GB2523616B - Use of quinolinone compound as hCBS enzyme inhibitor - Google Patents

Use of quinolinone compound as hCBS enzyme inhibitor

Info

Publication number
GB2523616B
GB2523616B GB1417893.3A GB201417893A GB2523616B GB 2523616 B GB2523616 B GB 2523616B GB 201417893 A GB201417893 A GB 201417893A GB 2523616 B GB2523616 B GB 2523616B
Authority
GB
United Kingdom
Prior art keywords
enzyme inhibitor
quinolinone compound
hcbs enzyme
hcbs
quinolinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1417893.3A
Other versions
GB2523616A (en
GB201417893D0 (en
Inventor
Yu Jing
Wu Fang
Zhou Yueyang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiaotong University
Original Assignee
Shanghai Jiaotong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiaotong University filed Critical Shanghai Jiaotong University
Publication of GB201417893D0 publication Critical patent/GB201417893D0/en
Publication of GB2523616A publication Critical patent/GB2523616A/en
Application granted granted Critical
Publication of GB2523616B publication Critical patent/GB2523616B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
GB1417893.3A 2013-10-09 2014-10-09 Use of quinolinone compound as hCBS enzyme inhibitor Expired - Fee Related GB2523616B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310467300.6A CN104546849B (en) 2013-10-09 2013-10-09 A kind of application of quinolinones compound as hCBS enzyme inhibitors

Publications (3)

Publication Number Publication Date
GB201417893D0 GB201417893D0 (en) 2014-11-26
GB2523616A GB2523616A (en) 2015-09-02
GB2523616B true GB2523616B (en) 2016-06-15

Family

ID=52001169

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1417893.3A Expired - Fee Related GB2523616B (en) 2013-10-09 2014-10-09 Use of quinolinone compound as hCBS enzyme inhibitor

Country Status (2)

Country Link
CN (1) CN104546849B (en)
GB (1) GB2523616B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4835599A (en) * 1998-06-29 2000-01-17 Edwin F. Ullman Assay for homocysteine
CA2802290A1 (en) * 2010-07-02 2011-12-05 Sygenta Participations Ag Novel microbiocidal dioxime ether derivatives
CN102393373B (en) * 2011-10-22 2013-05-08 温州市德福泰生物科技有限公司 Serum homocysteine measuring method and reagent for removing endogenous cystathionine disturbance
CN104560930B (en) * 2013-10-09 2018-04-03 上海交通大学 The combination target of hCBS enzyme specific inhibitors and its application

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications, Vol. 443(1), 2014 [available online 19 November 2013], (Pantouris, Georgios et al), pages 28-31, ISSN: 0006-291X *
Chemical Communications (Cambridge, United Kingdom), 2013 [published 24 October 2013], Vol. 49(100), (Zhou, Yueyang et al), pages 11782-11784 *
Journal of Organic Chemistry, Vol. 33(3), 1968, (Pettit, George R. et al), pages 1089-92, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
GB2523616A (en) 2015-09-02
GB201417893D0 (en) 2014-11-26
CN104546849A (en) 2015-04-29
CN104546849B (en) 2018-06-05

Similar Documents

Publication Publication Date Title
IL279682A (en) Benzoquinolone inhibitors of vmat2
HK1213251A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh idh 3--4---2-
EP3080100A4 (en) Inhibitors of lysine specific demethylase-1
EP2948450A4 (en) Metalloenzyme inhibitor compounds
EP3008051A4 (en) Metalloenzyme inhibitor compounds
HK1219271A1 (en) Compounds and compositions as inhibitors of mek mek
HK1203949A1 (en) Inhibitors of iap iap
HK1222339A1 (en) Inhibitors of metallo-ss-lactamase-enzymes --
EP3003372A4 (en) Inhibitors of complement factor h
HK1219273A1 (en) Novel inhibitor compounds of phosphodiesterase type 10a 10a
HK1214252A1 (en) Halogenopyrazoles as inhibitors of thrombin
HK1221645A1 (en) Benzoquinolone inhibitors of vmat2 vmat2
PL2888228T3 (en) Inhibitors of cd40-traf6 interaction
GB201312311D0 (en) Uses of enzyme inhibitors
GB2523615B (en) Use of Naphthalene-1,4-diketone compound as hCBS enzyme inhibitor
GB2523616B (en) Use of quinolinone compound as hCBS enzyme inhibitor
EP2959896A4 (en) Inhibitor of tprotein phosphorylation
FR2997080B1 (en) INHIBITORS OF NEPRILYSINE
GB201322036D0 (en) New therapeutic uses of enzyme inhibitors
GB201310488D0 (en) New therapeutic uses of enzyme inhibitors

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20181009